Central Venous Cannula Insertion

PROCEDURE2 trials

Sponsors

Mayo Clinic

Conditions

Chronic Myelomonocytic LeukemiaClonal Cytopenia of Undetermined SignificanceHigh Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsMetastatic Bladder Urothelial CarcinomaMetastatic Renal Pelvis and Ureter Urothelial CarcinomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Hodgkin LymphomaRecurrent Lymphoma

Phase 2

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

RecruitingNCT03418038

Mayo ClinicChronic Myelomonocytic Leukemia, Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements +5

Start: 2018-03-23End: 2033-11-02Target: 80Updated: 2026-03-18

Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers

RecruitingNCT07087860

Mayo ClinicMetastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma +3

Start: 2025-08-01End: 2028-08-07Target: 70Updated: 2025-12-09

Related Papers

LS1781 (Arm E): Phase II clinical trial to assess the safety and efficacy of high dose IV ascorbic acid with decitabine in newly diagnosed TET2 mutant chronic myelomonocytic leukemia (CMML)

Blood2025-11-03

Variability in interventional trials in clonal haematopoiesis

Blood2025-11-03

Phase II Trial Assessing Safety and Preliminary Efficacy of High-Dose Intravenous Ascorbic Acid and Decitabine in <i>TET2</i>-Mutant Chronic Myelomonocytic Leukemia

Blood2024-11-052 citations

High-dose IV ascorbic acid therapy for patients with CCUS with <i>TET2</i> mutations

Blood2024-10-0111 citations

Phase II Study Assessing Safety and Preliminary Efficacy of High Dose Intravenous Ascorbic Acid in Patients with <i>TET2</i> Mutant Clonal Cytopenias

Blood2023-11-023 citations

Phase II Study Assessing Safety and Preliminary Efficacy of High Dose Intravenous Ascorbic Acid in Patients with <i>TET2</i> Mutant Clonal Cytopenias of Undetermined Significance

Blood2022-11-152 citations

Phase II trial assessing safety and preliminary efficacy of high-dose intravenous ascorbic acid in patients with <i>TET2-</i>mutant clonal cytopenias of undetermined significance.

Journal of Clinical Oncology2022-06-013 citations